comparemela.com

Latest Breaking News On - Prostate cancer panel - Page 1 : comparemela.com

Lumpers vs Splitters: Categorizing Prostate Cancer

Should very low-risk and low-risk be combined into one?

United statesJames easthamCharles darwinJonathan epsteinDaniel sprattJohns hopkinsKevin sheeUniversity hospitals seidman cancer centerNational comprehensive cancer networkMemorial sloan kettering cancer centerAmerican urological associationGrade groupUniversity of california san franciscoProstate cancer panelMemorial sloan kettering urology serviceCase western reserve university in cleveland

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®.

United statesSan franciscoBenjamin lowentrittTracy mcgowanPaloma felicianoJanssen biotech incNational comprehensive cancer network incAmerican urological associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesProstate cancer panelJanssen scientific affairsUs medical affairsNone of the janssen pharmaceutical companies

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence dat.

United statesSan franciscoBenjamin lowentrittTracy mcgowanPaloma felicianoJanssen biotech incNational comprehensive cancer network incAmerican urological associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesProstate cancer panelJanssen scientific affairsUs medical affairsNone of the janssen pharmaceutical companies

New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®.

United statesSan franciscoBenjamin lowentrittTracy mcgowanPaloma felicianoJanssen biotech incNational comprehensive cancer network incAmerican urological associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesProstate cancer panelJanssen scientific affairsUs medical affairsNone of the janssen pharmaceutical companies

After Doc Uproar, NCCN Reverses Prostate Cancer Guidance

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone preferred initial treatment option.

New yorkUnited statesNorthwestern universityMatthew cooperbergStacy loebEdward schaefferLurie comprehensive cancer centerProstate cancer panelUniversity of california san franciscoNational comprehensive cancer networkMedscape medical newsCancer panelActive surveillanceCalifornia san franciscoProstate carcinomaAlignant prostate neoplasm

vimarsana © 2020. All Rights Reserved.